According to the research report titled ‘Global Rheumatoid Arthritis Market (2021 Edition) - Analysis By Drug Type (NSAIDs, DMARDs, Corticosteroids, Others), Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global rheumatoid arthritis market was valued at USD 24.46 billion in the year 2020 and is slated to record tremendous expansion during 2021-2026.

Rising proportion of aging population coupled with the growing number of smokers, both of which lead to a greater risk of developing this ailment are parameters contributing to global rheumatoid arthritis industry expansion.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4383305/   

Moreover, massive funds given to academic research institutions as well as individual researchers to boost the studies on new drugs and treatments are supporting the market development. 

Besides, rising initiatives undertaken by international agencies like World Health Organization (WHO) and National Institute of health (NIH) for the prevention of chronic disorders like cancer, rheumatoid arthritis, and cardiovascular diseases are expected to further accelerate the progress of the business sphere during the review period. 

Based on drug type, the market is split into DMARDs (disease-modifying anti-rheumatic drug), and NSAIDs (non-steroidal anti-inflammatory drug). Of these, the DMARDs vertical is anticipated to witness substantial growth during the projected timeline, owing to the launch of novel therapeutic agents, supportive reimbursement policies for expensive treatments, and global increase in the prevalence of rheumatoid arthritis.  

In terms of treatment, global rheumatoid arthritis market is segregated into joint fusion, joint replacement, tendon repair, and others. As per diagnosis type, the business sphere is divided into ESR (erythrocyte sedimentation rate), and CRP (creative protein test).

Speaking of geographical terrain, Americas market accounted for a significant revenue share in 2020 and is poised to record stellar growth during the assessment timeframe, ascribed to the widespread availability of well-developed medical infrastructure, a large patient base, and growing awareness about the treatment facilities in the area. Additionally, the higher adoption rate of biopharmaceuticals for the treatment, coupled with the soaring geriatric population is further aiding regional industry expansion. 

The key players amplifying the competitive hierarchy of worldwide rheumatoid arthritis market include Gilead Sciences Inc., Merck KGaA, Galapagos NV, Sanofi S.A., Pfizer Inc., Eli Lilly Company, Cipla Limited, Amgen Inc., Johnson & Johnson, Bristol Myers Squibb, and F. Hoffmann-La Roche Ltd. among others.